
Teva Pharmaceutical (TEVA) Stock Forecast & Price Target
Teva Pharmaceutical (TEVA) Analyst Ratings
Bulls say
Teva Pharmaceutical Indus is well-positioned for strong growth in the coming years due to its leading position in the generic drug market, a significant presence in key global markets, and a diverse portfolio of innovative medicines and biosimilars in the neurology and immunology fields. The recent acquisition of Emalex Biosciences highlights the company's strategic focus on expanding its portfolio in areas with high unmet medical needs, such as pediatric Tourette's Syndrome. With a strong pipeline and a focus on incremental innovation, Teva is poised for success and has the potential to become a top player in the global pharmaceutical industry.
Bears say
Teva Pharmaceutical Indus is facing challenges due to channel inventory timing and the potential for slowing growth in 2Q. Their focus on generics could be affected by sampling, negotiation, and onboarding delays. Overall, management is executing well on their Pivot to Growth plan. However, risks such as regulatory uncertainties and pipeline execution could impact their potential to reach a 30% op margin by 2027.
This aggregate rating is based on analysts' research of Teva Pharmaceutical and is not a guaranteed prediction by Public.com or investment advice.
Teva Pharmaceutical (TEVA) Analyst Forecast & Price Prediction
Start investing in Teva Pharmaceutical (TEVA)
Order type
Buy in
Order amount
Est. shares
0 shares